ClouDr Group's (HKG:9955) diabetes-related digital drug product, ClouDT-01, was approved by China's Zhejiang Medical Products Administration and received a medical device registration
certificate.
ClouDT-01 is meant to be a complete diabetes management solution that benefits from artificial intelligence and real-time responses, according to a Thursday filing with the Hong Kong bourse.
The company's shares closed 8% higher on Thursday.
Price (HKD): $1.20, Change: $+0.090, Percent Change: +8.11%